Hypomagnesemia
Conditions
Brief summary
Hypomagnesemia is a common entity in the inpatient and outpatient setting. in previous retrospective study hypomagnesemic patients have higher mortality and longer hospitalization. whether hypomagnesemia is merely a marker of poor prognosis, or whether replacing it can improve outcomes is unclear. The current standard of care is to discharge these patients without workup or further treatment, even if patients had received intravenous therapy while hospitalized. The investigator wish to examine prospectively whether giving replacement therapy affects mortality, length of hospital stay and overall well-being. In order to replete intracellular levels and replete magnesium stores, magnesium should be given for several months.
Interventions
DRUGMagnesium Citrate 100 MG
initial intravenous treatment: Patients with magnesium levels 1-1.5 mg/dL will receive 2-4 grams of magnesium sulfate in the first 24 hours. Patients with magnesium levels 1.6-1.9 mg/dL will receive 1 gram of magnesium sulfate. participants with magnesium level ≥1 mg/dL, will be randomized, and oral magnesium therapy, Magnesium Citrate, ( or no treatment) will be started, and continued for at least three months. The experimental group will receive 400mg magnesium daily in two divided doses.
Sponsors
Frieda Wolf
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Any patient admitted over the age of 18, has hypomagnesemia (magnesium level ≤1.9 mg/dL) and is able to give consent.
Exclusion criteria
* A patient unable to give consent. * A patient admitted for an elective procedure. * A patient in critical condition or dying. * Patients with advanced kidney disease with eGFR\<15ml/min or on dialysis. * Patients with severe diarrhea, precluding use of magnesium citrate. * Patients already receiving magnesium supplements. * Patients with severe malnutrition or life-threatening hypomagnesemia (serum level \<1mg/dL), requiring intravenous and oral replacement of magnesium.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| compare mortality | one year | To compare mortality between the population receiving magnesium and the population receiving standard care: ie no replacement. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hospitalization | one year | Length in days of hospitalization. |
Other
| Measure | Time frame | Description |
|---|---|---|
| causes for hypomagnesemia | one year | The investigators will attempt to ascertain the causes for hypomagnesemia from the data collected (medications, diarrhea, malnutrition, etc) |
| re-hospitalization | one year | re-hospitalization for any cause |
| Subjective well-being | one year | symptoms and overall well-being of the patients: a questionaire will be administered at the beginning of the study and at each visit regarding subjective feelings of well being, symptoms of pain, cramping and diarrhea, and overall functional capacity |
Countries
Israel
Contacts
Primary ContactFrieda Wolf
Backup ContactRotem Shvartzman
Outcome results
None listed